203934-60-5 Usage
Uses
Used in Organic Synthesis:
2,8-Diaza-spiro[4.5]decane-3,8-dicarboxylic acid 8-tert-butyl ester 3-ethyl ester is used as a building block in organic synthesis for the creation of new compounds. Its unique structure allows for versatile chemical reactions, making it a valuable component in the synthesis of complex organic molecules.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 2,8-Diaza-spiro[4.5]decane-3,8-dicarboxylic acid 8-tert-butyl ester 3-ethyl ester is used as a precursor in drug development. Its distinctive molecular framework can be utilized to design and synthesize novel pharmaceuticals with potential therapeutic applications.
Used in Materials Science:
2,8-Diaza-spiro[4.5]decane-3,8-dicarboxylic acid 8-tert-butyl ester 3-ethyl ester is also used in materials science for the development of new materials. Its structural properties may contribute to the creation of innovative materials with unique properties, such as improved stability or specific interactions with other molecules.
Further research on the properties and potential applications of 2,8-Diaza-spiro[4.5]decane-3,8-dicarboxylic acid 8-tert-butyl ester 3-ethyl ester could lead to significant advancements in various scientific and industrial fields, including drug development and materials science.
Check Digit Verification of cas no
The CAS Registry Mumber 203934-60-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,0,3,9,3 and 4 respectively; the second part has 2 digits, 6 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 203934-60:
(8*2)+(7*0)+(6*3)+(5*9)+(4*3)+(3*4)+(2*6)+(1*0)=115
115 % 10 = 5
So 203934-60-5 is a valid CAS Registry Number.
203934-60-5Relevant articles and documents
Compound as apoptosis protein inhibitor, and application thereof
-
, (2018/09/12)
The present invention belongs to the field of medical chemistry, relates to a class of compounds of apoptosis protein inhibitors, and applications thereof, and particularly provides a compound represented by a formula I, or an isomer thereof, a pharmaceut
Novel spiroketal pyrrolidine GSK2336805 potently inhibits key hepatitis C virus genotype 1b mutants: From lead to clinical compound
Kazmierski, Wieslaw M.,Maynard, Andrew,Duan, Maosheng,Baskaran, Sam,Botyanszki, Janos,Crosby, Renae,Dickerson, Scott,Tallant, Matthew,Grimes, Rick,Hamatake, Robert,Leivers, Martin,Roberts, Christopher D.,Walker, Jill
, p. 2058 - 2073 (2014/04/03)
Rapid clinical progress of hepatitis C virus (HCV) replication inhibitors, including these selecting for resistance in the NS5A region (NS5A inhibitors), promises to revolutionize HCV treatment. Herein, we describe our explorations of diverse spiropyrrolidine motifs in novel NS5A inhibitors and a proposed interaction model. We discovered that the 1,4-dioxa-7-azaspiro[4.4]nonane motif in inhibitor 41H (GSK2236805) supported high potency against genotypes 1a and 1b as well as in genotype 1b L31V and Y93H mutants. Consistent with this, 41H potently suppressed HCV RNA in the 20-day RNA reduction assay. Pharmacokinetic and safety data supported further progression of 41H to the clinic.